OncoMatch/Clinical Trials/NCT04807673
Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)
Is NCT04807673 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Pembrolizumab and Paclitaxel for esophageal squamous cell carcinoma.
Treatment: Pembrolizumab · Paclitaxel · Cisplatin — The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus paclitaxel, cisplatin as neoadjuvant therapy followed by surgery, and pembrolizumab as adjuvant therapy, compared with neoadjuvant chemoradiotherapy and surgery for locally advanced ESCC in multicenter.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage CT1-3N1-2M0, CT2-3N0M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: operation
Prior therapy (operation, radiotherapy, immunotherapy, or chemotherapy) for esophageal cancer
Cannot have received: radiotherapy
Prior therapy (operation, radiotherapy, immunotherapy, or chemotherapy) for esophageal cancer
Cannot have received: immunotherapy
Prior therapy (operation, radiotherapy, immunotherapy, or chemotherapy) for esophageal cancer
Cannot have received: chemotherapy
Prior therapy (operation, radiotherapy, immunotherapy, or chemotherapy) for esophageal cancer
Cannot have received: chemotherapy
Patient has received prior chemotherapy, radiotherapy, target therapy ，and immune therapy for this malignancy or any other past malignancy
Cannot have received: radiotherapy
Patient has received prior chemotherapy, radiotherapy, target therapy ，and immune therapy for this malignancy or any other past malignancy
Cannot have received: target therapy
Patient has received prior chemotherapy, radiotherapy, target therapy ，and immune therapy for this malignancy or any other past malignancy
Cannot have received: immune therapy
Patient has received prior chemotherapy, radiotherapy, target therapy ，and immune therapy for this malignancy or any other past malignancy
Lab requirements
Blood counts
Kidney function
Liver function
Demonstrate adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify